Zacks: Analysts Expect Illumina, Inc. (ILMN) Will Announce Quarterly Sales of $735.16 Million
Analysts forecast that Illumina, Inc. (NASDAQ:ILMN) will post sales of $735.16 million for the current quarter, Zacks reports. Seven analysts have provided estimates for Illumina’s earnings, with the lowest sales estimate coming in at $728.41 million and the highest estimate coming in at $741.30 million. Illumina reported sales of $619.35 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 18.7%. The company is expected to issue its next quarterly earnings results on Tuesday, January 30th.
On average, analysts expect that Illumina will report full-year sales of $735.16 million for the current year, with estimates ranging from $2.70 billion to $2.72 billion. For the next fiscal year, analysts forecast that the business will post sales of $3.07 billion per share, with estimates ranging from $2.97 billion to $3.19 billion. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Illumina.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating the consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The company had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. During the same period last year, the company earned $0.97 earnings per share. Illumina’s quarterly revenue was up 17.6% compared to the same quarter last year.
In other Illumina news, SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $202.23, for a total transaction of $29,323.35. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $226.55, for a total value of $283,187.50. Following the transaction, the director now directly owns 9,088 shares in the company, valued at approximately $2,058,886.40. The disclosure for this sale can be found here. Insiders sold 136,421 shares of company stock worth $28,489,101 over the last ninety days. Corporate insiders own 0.89% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in Illumina by 2.6% during the second quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock worth $1,718,601,000 after buying an additional 255,498 shares during the last quarter. Ameriprise Financial Inc. raised its position in Illumina by 3.1% in the third quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock valued at $500,416,000 after purchasing an additional 76,452 shares during the period. Capital World Investors raised its position in Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after purchasing an additional 410,000 shares during the period. TIAA CREF Investment Management LLC raised its position in Illumina by 55.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after purchasing an additional 527,548 shares during the period. Finally, Winslow Capital Management LLC purchased a new stake in Illumina in the second quarter valued at $211,584,000. 91.75% of the stock is currently owned by institutional investors.
Shares of Illumina (NASDAQ ILMN) opened at $214.11 on Tuesday. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. Illumina has a 1-year low of $121.47 and a 1-year high of $230.72. The company has a market capitalization of $31,776.90, a P/E ratio of 63.64, a price-to-earnings-growth ratio of 3.59 and a beta of 0.79.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.